Hepatitis C Antibody Seroconversion after Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
1James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, 2Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, 3Faith & Health Division, Methodist Le Bonheur Healthcare, Memphis, TN
Meeting: 2020 American Transplant Congress
Abstract number: D-172
Keywords: Hepatitis, Hepatitis C, Infection, Kidney transplantation
Session Information
Session Name: Poster Session D: Non-Organ Specific: Viral Hepatitis
Session Type: Poster Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
Location: Virtual
*Purpose: We aimed to assess factors associated with hepatitis C virus (HCV) seroconversion among HCV seronegative kidney transplant candidates receiving HCV infected donor kidneys.
*Methods: This is a retrospective review examining HCV antibody seroconversion of all kidney transplant recipients receiving an organ from an HCV infected donor between March 1st, 2018 and May 1st, 2019 at a high-volume kidney transplant center in the southeast United States.
*Results: Out of 91 patients receiving HCV infected kidneys, the final cohort consisted of 76 recipients with 4 (5.1%) recipients noted to have HCV antibody seroconversion in the setting of HCV viremia. No significant differences in type of immunosuppression was noted between the HCV antibody positive group and HCV antibody negative group. There was delayed emergence of HCV antibody with time with achievement of a sustained virologic response once patients completed HCV antiviral therapy.
| At time of Transplantation | 4-weeks after transplantation | 8-weeks after transplantation | 12-weeks after transplantation | SVR12 | |
| Median Viral Load, IU/mL (IQR) | 0 | 524000 (174000 – 1940000) | 39655 (0 – 146000) | 7.5 ( 0 – 62) | 0 |
| Median AST, units/L (IQR) | 24 (16 – 33) | 22 (16 – 40) | 29 (21 – 51) | 21 (16 – 34) | 19 (16 – 22) |
| Median ALT, units/L (IQR) | 24 (19 – 30) | 41 (30 – 69) | 52 (34 – 71) | 33 (25 – 48) | 30 (23 – 35) |
| Median Creatinine mg/dL (IQR) | 8.47 (6.73 – 10.67 ) | 1.48 (1.27 – 1.77) | 1.41 (1.21 – 1.67) | 1.30 (1.11 – 1.7) | 1.29 (1.11 – 1.58) |
| Median eGFR, ml/min/1.73 m2 (IQR) | 7 (5 – 9) | 55 (42 – 65) | 58 (49 – 69) | 61 (50 – 73) | 68 (55 – 75) |
| HCV Antibody Present, n (%) | – | 1 (16.7) of 6 | 2 (20%) of 10 | 2 (15.4%) of 13 | 4 (5.3%) of 76 |
*Conclusions: HCV antibody should not be considered routine screening for the presence of infection in previously HCV-naïve kidney transplant candidates receiving kidneys from HCV infected donors. The assessment of HCV viral load should be routine in all transplant recipients receiving organs from public health service increased risk donors.
To cite this abstract in AMA style:
Agbim UA, Cseprekal O, Yazawa M, Talwar M, Balaraman V, Bhalla A, Podila PS, Maliakkal B, Nair S, Eason JD, Molnar MZ. Hepatitis C Antibody Seroconversion after Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/hepatitis-c-antibody-seroconversion-after-transplantation-of-kidneys-from-hepatitis-c-infected-donors-to-hepatitis-c-negative-recipients/. Accessed May 16, 2025.« Back to 2020 American Transplant Congress